Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of subcutaneous blinatumomab in relapsed/refractory or MRD-positive B-cell precursor acute lymphoblastic leukemia
NL-OMON61025Phase 2Suspended
- Sponsor
- Amgen
- Start
- Apr 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) and B cell acute lymphoblastic leukemia (B-ALL) (6 arms), sponsored by Amgen. Primary endpoints: Dose-limiting toxicities and adverse events in dose escalation, CR/CRh within first 2 cycles in dose expansion and 3 more. Started Apr 2023; status: suspended.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NL-OMON61025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61025.